Intraportal versus Systemic Pentoxifylline Infusion after Normothermic Liver Ischemia: Effects on Regional Blood Flow Redistribution and Hepatic Ischemia-Reperfusion Injury
Pentoxifylline (PTX) has been shown to have beneficial effects on microcirculatory blood flow. In this study we evaluate the potential hemodynamic and metabolic benefits of PTX during hepatic ischemia. We also test the hypothesis that portal PTX infusion can minimize the I/R injury when compared to systemic infusion. Methods. Twenty-four dogs ( ?kg) were subjected to portal triad occlusion (PTO) for 45?min. The animals were assigned to 3 groups: CT (control, PTO, ), PTX-syst (PTO + 25?mg/Kg of PTX IV, ), and PTX-pv (PTO + 25?mg/Kg of PTX in the portal vein, ). Animals were followed for 120?min. Systemic hemodynamics, gastrointestinal tract perfusion, oxygen-derived variables, and liver enzymes were evaluated throughout the experiment. Results. Animals treated with PTX presented significantly higher CO in the first hour after reperfusion, when compared to the CT (~3.7 vs. 2.1?L/min, ). Alanine aminotransferase (ALT) was similar in the PTX groups two hours after reperfusion but significantly higher in the CT (227 vs. ~64?U/L, ). Conclusion. PTX infusion was associated with hemodynamic benefits and was able to minimize liver injury during normothermic hepatic I/R. However, local PTX infusion was not associated with any significant advantage over systemic route. 1. Introduction Despite technical advances in liver surgery in the last decades, the consequences of liver ischemia/reperfusion injury remain a major concern for surgeons. Liver ischemia/reperfusion (I/R) injury is a complex cascade of events mediated by numerous inflammatory cells and molecular mediators, resulting in hepatocyte death and systemic inflammatory response. The degree of inflammatory response and organ dysfunction is dependent on duration of liver ischemia and underlying liver disease. In this setting, activation of hepatic macrophages plays an important role. Macrophages have been responsible for the release of various inflammatory mediators, including but not limited to tumor necrosis factor alpha (TNF-α). Several studies have shown that the inhibition of TNF-α production or its neutralization after isolated hepatic I/R decreases polymorphonuclear neutrophil infiltration with further reduction of the I/R injury [1–3]. Pentoxifylline (PTX) is a methylxanthine derivative that displays vasodilatory effects on peripheral blood vessels, particularly on the liver [4–8]. In addition, PTX has other important pharmacological properties that may be responsible for the minimization of hepatic I/R including; attenuation of leukocyte-endothelial interactions, reduction of blood viscosity, and
References
[1]
M. F. Mahmoud, S. M. El Shazly, and W. Barakat, “Inhibition of TNF-α protects against hepatic ischemia-reperfusion injury in rats via NF-κB dependent pathway,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 385, no. 5, pp. 465–471, 2012.
[2]
Y.-L. Yang, J.-P. Li, X.-P. Xu, K.-F. Dou, S.-Q. Yue, and K.-Z. Li, “Protective effects of tumor necrosis factor α antibody and ulinastatin on liver ischemic reperfusion in rats,” World Journal of Gastroenterology, vol. 10, no. 21, pp. 3161–3164, 2004.
[3]
L. M. Colletti, D. G. Remick, G. D. Burtch, S. L. Kunkel, R. M. Strieter, and D. A. Campbell Jr., “Role of tumor necrosis factor-α in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat,” Journal of Clinical Investigation, vol. 85, no. 6, pp. 1936–1943, 1990.
[4]
A. Aslan, G. Karagüzel, M. ?elik, N. Uysal, G. Yücel, and M. Meliko?lu, “Pentoxifylline contributes to the hepatic cytoprotective process in rats undergoing hepatic ischemia and reperfusion injury,” European Surgical Research, vol. 33, no. 4, pp. 285–290, 2001.
[5]
P. Marteau, F. Ballet, Y. Chretien, C. Rey, P. Jaillon, and R. Poupon, “Effect of vasodilators on hepatic microcirculation: a study of the inhibition of norepinephrine-induced vasoconstriction in the isolated perfused rat liver,” Hepatology, vol. 8, no. 2, pp. 228–231, 1988.
[6]
E. Vardareli, T. Saricam, T. Koken, I. Degirmenci, E. Aral, and E. Erenoglu, “The effect of alpha-tocopherol and pentoxyfilline on ischemia-reperfusion induced liver injury in rats,” Hepato-Gastroenterology, vol. 45, no. 23, pp. 1505–1508, 1998.
[7]
L. Kaptanoglu, M. Kapan, S. Kapan, E. Goksoy, and H. Oktar, “Effects of nimodipine and pentoxyfylline in prevention of hepatic ischemic damage in rats at normal and hypothermic conditions,” European Journal of Pharmacology, vol. 587, no. 1–3, pp. 253–256, 2008.
[8]
J. M. Müller, B. Vollmar, and M. D. Menger, “Pentoxifylline reduces venular leukocyte adherence (“reflow paradox”) but not microvascular “no reflow” in hepatic ischemia/reperfusion,” Journal of Surgical Research, vol. 71, no. 1, pp. 1–6, 1997.
[9]
D. L. Mollitt and N. D. Poulos, “The role of pentoxifylline in endotoxin-induced alterations of red cell deformability and whole blood viscosity in the neonate,” Journal of Pediatric Surgery, vol. 26, no. 5, pp. 572–574, 1991.
[10]
R. J. Cruz Jr., M. M. Yada-Langui, L. F. Poli-de-Figueiredo, S. Sinosaki, and M. Rocha-e-Silva, “The synergistic effects of pentoxifylline on systemic and regional perfusion after hemorrhage and hypertonic resuscitation,” Anesthesia and Analgesia, vol. 102, no. 5, pp. 1518–1524, 2006.
[11]
M. M. Yada-Langui, E. A. Anjos-Valotta, P. Sannomiya, M. Rocha-e-Silva, and R. Coimbra, “Resuscitation affects microcirculatory polymorphonuclear leukocyte behavior after hemorrhagic shock: role of hypertonic saline and pentoxifylline,” Experimental Biology and Medicine, vol. 229, no. 7, pp. 684–693, 2004.
[12]
H.-I. Lin, S.-J. Chu, D. Wang, and N.-H. Feng, “Pharmacological modulation of TNF production in macrophages,” Journal of Microbiology, Immunology and Infection, vol. 37, no. 1, pp. 8–15, 2004.
[13]
Z. Tong, B. Chen, H. Dai, P. C. Bauer, J. Guzman, and U. Costabel, “Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages,” Annals of Allergy, Asthma and Immunology, vol. 92, no. 2, pp. 234–239, 2004.
[14]
R. Coimbra, A. Razuk-Filho, M. M. Yada-Langui, and M. Rocha-e-Silva, “Intraarterial pulmonary pentoxifylline improves cardiac performance and oxygen utilization after hemorrhagic shock: a novel resuscitation strategy,” Anesthesia and Analgesia, vol. 98, no. 5, pp. 1439–1446, 2004.
[15]
A. El-Ghoneimi, R. Cursio, A. Schmid-Alliana et al., “Pentoxifylline inhibits liver expression of tumor necrosis factor alpha mRNA following normothermic ischemia-reperfusion,” HPB, vol. 9, no. 2, pp. 112–119, 2007.
[16]
A. El-Ghoneimi, R. Cursio, A. Schmid-Alliana et al., “Inhibition of tumor necrosis factor alpha gene transcription by pentoxifylline reduces normothermic liver ischemia-reperfusion injury in rats,” Transplantation Proceedings, vol. 39, no. 6, pp. 1761–1764, 2007.
[17]
N. F. Cerqueira, C. A. Hussni, W. B. Yoshida, J. L. Sequeira, and C. R. Padovani, “Effects of pentoxifylline and n-acetylcysteine on injuries caused by ischemia and reperfusion of splanchnic organs in rats,” International Angiology, vol. 27, no. 6, pp. 512–521, 2008.
[18]
R. J. Cruz Jr., L. F. Poli-de-Figueiredo, J. L. M. Braz, E. A. Diniz, and M. Rocha-e-Silva, “Systemic and regional effects of supraceliac aortic occlusion during experimental hepatic vascular exclusion,” American Journal of Surgery, vol. 185, no. 4, pp. 388–393, 2003.
[19]
E. A. Ribeiro, R. J. Cruz Jr., L. F. Poli-de-Figueiredo, O. Rojas, and M. Rocha-e-Silva, “Active spleno-femoral shunt avoids splanchnic congestion during portal triad occlusion: an experimental study,” Transplantation Proceedings, vol. 37, no. 5, pp. 2347–2350, 2005.
[20]
R. J. Cruz Jr., A. G. Garrido, C. M. F. Ribeiro, T. Harada, and M. Rocha-e-Silva, “Regional blood flow distribution and oxygen metabolism during mesenteric ischemia and congestion,” Journal of Surgical Research, vol. 161, no. 1, pp. 54–61, 2010.